bioRxivNeurosciencePreprint
A new drug candidate for glycogen storage disorders enhances glycogen catabolism: Lessons from Adult Polyglucosan Body Disease models
Hilla VakniniD, Kumudesh MishraiD, Jeevitha D’Souza, Monzer MarisatiD, Uri SprecheriD, Shane Wald-Altman, Anna DukhovnyiD, Yuval RaviviD, Benny Da’adooshiD, Hamutal EngeliD, Sandrine Benhamron, Keren NitzaniD, Anna PermyakovaiD, Hanna Rosenmann, Alexander LossosiD, Joseph TamiD, Berge Arakel MinassianiD, Or KakhloniD, Miguel WeiliD
Abstract
This work employs Adult Polyglucosan Body Disease (APBD) models to explore the efficacy and mechanism of action of 144DG11, a new polyglucosan-reducing lead compound discovered by a high-throughput screen (HTS). APBD is an adult onset glycogen storage disorder (GSD) manifesting as a debilitating progressive axonopathic leukodystrophy. APBD is caused by glycogen branching enzyme (GBE) deficiency leading to poorly branched and insoluble glycogen inclusions, which precipitate as neuropathogenic polyglucosans (PG). 144DG11 led to prolonged survival and improved motor parameters in a GBE knockin (Gbeys/ys) APBD mouse model. Histopathologically, 144DG11 reduced PG and glycogen levels in brain, liver, heart, and peripheral nerve. Indirect calorimetry experiments revealed that 144DG11 increases carbohydrate burn at the expense of fat burn, suggesting metabolic mobilization of pathogenic PG. These results were also reflected at the cellular level by increased glycolytic, mitochondrial and total ATP production. Mechanistically, we show that the molecular target of 144DG11 is the lysosomal membrane protein LAMP1, whose interaction with the compound, similar to LAMP1 knockdown, enhanced autolysosomal degradation of glycogen and lysosomal acidification. Enhanced mitochondrial activity and lysosomal modifications were also the most pronounced effects of 144DG11 in APBD patient fibroblasts as discovered by image-based multiparametric phenotyping analysis and corroborated by proteomics. In summary, this work presents a broad mechanistic and target-based characterization of 144DG11 in in vivo and cell models of the prototypical GSD APBD. This investigation warrants development of 144DG11 into a safe and efficacious GSD therapy. One Sentence SummaryA new compound, demonstrated to ameliorate APBD in vivo and ex vivo by autophagic catabolism of glycogen, may potentially become a universal drug for glycogen storage disorders.
- organism: mouse
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Targeted glycophagy ATG8 therapy reverses diabetic heart disease in mice and in human engineered cardiac tissues
Kimberley M. Mellor, Upasna Varma, … Lea M.D. Delbridge·Nature Cardiovascular ResearchPeer-reviewed·Sep 29, 2025
- Glucosylceramide depletion disrupts endolysosomal function in GBA-linked Parkinsons fibroblasts?
M. Bhardwaj, Z. Kula, … D. J. Sillence·bioRxiv·Nov 30, 2023
- Protective role of the Atg8 1 homologue Gabarapl1 in regulating cardiomyocyte glycophagy in diabetic heart disease
Kimberley M. Mellor, Upasna Varma, … Lea M.D. Delbridge·bioRxiv·Jun 21, 2021
- Skeletal muscle effects of antisense oligonucleotides targeting glycogen synthase 1 in a mouse model of Pompe disease
Lan Nguyen Weiss, Michele Carrer, … Virginia E. Kimonis·Clinical and Translational MedicinePeer-reviewed·Apr 1, 2025
- Disease-associated programming of cell memory in glycogen storage disorder type 1a
Uri Sprecher, J D’Souza, … Miguel Weil·bioRxiv·Feb 20, 2023
- Glucocerebrosidase Deficiency Dysregulates Human Astrocyte Lipid Metabolism
Aboud Tahanis, Thao Nguyen, … Robert Krencik·bioRxiv·Jan 9, 2025